Sunday, October 23, 2016

Daypro


Daypro is a brand name of oxaprozin, approved by the FDA in the following formulation(s):


DAYPRO (oxaprozin - tablet; oral)



  • Manufacturer: GD SEARLE

    Approval date: October 29, 1992

    Strength(s): 600MG [RLD][AB]

Has a generic version of Daypro been approved?


Yes. The following products are equivalent to Daypro:


oxaprozin tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: September 2, 2004

    Strength(s): 600MG [AB]


  • Manufacturer: CARACO

    Approval date: January 3, 2002

    Strength(s): 600MG [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: January 31, 2001

    Strength(s): 600MG [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: May 13, 2002

    Strength(s): 600MG [AB]


  • Manufacturer: MYLAN

    Approval date: February 28, 2001

    Strength(s): 600MG [AB]


  • Manufacturer: SANDOZ

    Approval date: January 31, 2001

    Strength(s): 600MG [AB]


  • Manufacturer: TEVA

    Approval date: July 3, 2002

    Strength(s): 600MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: February 9, 2001

    Strength(s): 600MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daypro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Daypro.

See also...

  • Daypro Consumer Information (Wolters Kluwer)
  • Daypro Consumer Information (Cerner Multum)
  • Daypro Advanced Consumer Information (Micromedex)
  • Oxaprozin Consumer Information (Wolters Kluwer)
  • Oxaprozin Consumer Information (Cerner Multum)
  • Oxaprozin Advanced Consumer Information (Micromedex)
  • Oxaprozin AHFS DI Monographs (ASHP)
  • Oxaprozin Potassium AHFS DI Monographs (ASHP)

No comments:

Post a Comment